| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 385.08% | £339,553.44 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 313.56% | £289,488.73 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 217.60% | £222,319.13 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | 50.45% | £105,317.22 | |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 48.33% | £103,830.28 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 37.67% | £96,367.88 |
| Lord Mance |
|
Stryker / NYQ:SYK | 22.45% | £85,715.63 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | 1.96% | £71,370.88 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | -3.98% | £67,214.67 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -16.42% | £58,503.53 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -38.61% | £42,971.69 |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** |